Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895199 | 0.82 | IKBKB (0.46) | ADORA2AADORA1MIFALPLALPG | |
| SCHEMBL17895085 | 0.78 | IKBKB (0.48) | ADORA2AADORA1MEN1KMT2ARXFP1 | |
| SCHEMBL19786871 | 0.77 | IKBKB (0.40) | ADORA2AADORA1MIFMEN1KMT2A | |
| SCHEMBL17895237 | 0.77 | BRD4 (0.47) | ADORA2AADORA1MEN1KMT2ARXFP1 | |
| SCHEMBL17895072 | 0.75 | BRD4 (0.49) | BRD4IKBKBCHUK | |
| SCHEMBL17895242 | 0.74 | ADORA2A (0.45) | ADORA2AADORA1MIFIKBKBCHUK | |
| SCHEMBL17895272 | 0.74 | ALDH1A1 (0.37) | ADORA2AADORA1MIFALPLALPG | |
| SCHEMBL22099675 | 0.72 | BRD4 (0.40) | BRD4 | |
| SCHEMBL22099671 | 0.72 | BRD4 (0.40) | BRD4 | |
| SCHEMBL17895083 | 0.71 | ADORA2A (0.42) | ADORA2AADORA1MIFHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | UNIVERSITE DE MONTPELLIER (FR) | 2020-06-23 | — | — | US | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689384-B2 | Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer | NQO1, NQO2, ABL1 | ADORA2A 1104/4885ADORA1 1036/4885MIF 3073/4885 |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | NQO1, NQO2, ABL1 | ADORA2A 1104/4885ADORA1 1036/4885MIF 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.